EQT Life Sciences joins USD 115 million Series A round in UK biotech RQ Bio

  • EQT AB, via EQT Life Sciences, joined a USD 115 million Series A round in UK biotech RQ Bio, led by Frazier Life Sciences.
  • RQ Bio develops antibody therapies to prevent influenza in high-risk and immunocompromised patients, targeting season-long protection from a single administration.
  • Proceeds will fund clinical development of lead program RQB01, with additional investment to expand a broader infectious-disease pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQT AB published the original content used to generate this news brief on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.